Matter Bio, a Brooklyn-based biotech company dedicated to preserving genome integrity and extending human lifespan, announced the closing of a $7 million seed funding round. The round was led by Lifespan Vision Ventures with additional support from quadraScope Ventures and grants from NIH, NCI, and NIEHS. The funds will enable Matter Bio to advance its research on the information theory of aging at a genomic level and support the filing of an IND and the start of a Phase 1/2a clinical trial in solid cancer. Founded by renowned scientists including George Church, Jan Vijg, and Claudia Gravekamp, the company aims to tackle genome instability using a multi-faceted approach that includes detecting mutation, correcting integrated mutations, and eliminating irreparable cells. The company is positioned at the forefront of longevity biotechnology. Lifespan Vision Ventures’ investment aligns with its mission to support cutting-edge aging solutions. For more details, visit matterbio.com.
Biotechnology, Healthcare, Venture Capital,United States, New York
https://contentapi.cision.com/api/v1.0/releases/20240529EN25665